J. Janssen (Nijmegen, The Netherlands), E. Clini (Pavullo, Italy)
Which functional alteration is mainly the cause in determining dyspnoeain COPD patients?
G. Bruni, S. Granieri, A. Bruni (Cosenza, Italy)
|  |
The evaluation of respiratory muscle functions in patients with severe COPD
Y. Turgut, H. D. Ikitimur, T. Demir, S. Umut (Istanbul, Turkey)
| |
Our experiences in COPD treatment following GOLD implementation in Croatia
B. Butorac Petanjek, D. Vrankovic, D. Pelicaric, M. Krizanic Jurisic, A. Rozman (Zagreb, Croatia)
| |
The evaluation of dynamic hyperinflation in cases with COPD
H. D. Ikitimur, C. Akman, T. Demir, N. Yildirim (Istanbul, Turkey)
| |
How the bronchodilatator in COPD patients works
G. Bruni, S. Granieri, A. Bruni (Cosenza, Italy)
| |
Effect of inhaled salt-bromide-iodine thermal water on airway inflammation in COPD
M. Pellegrini, D. Fanin, Y. Nowiki, G. Guarnieri, A. Bordin, P. Maestrelli (Padova, Italy)
| |
Spirometric outcomes of COPD patients with tiotropium compared with salmeterol according to previous maintenance long-acting beta-agonist use
S. J. Langley, D. Briggs, Jr., S. Bhattacharya, S. Kesten, C. Cassino (Manchester, United Kingdom; Birmingham, Ridgefield, United States Of America)
| |
Tiotropium bromide in real life: early experience with a new drug. A new perspective for COPD patients
I. N. Fiks, J. M. Barros, T. Antunes (Sao Paulo, Brazil)
| |
The efficacy of salmeterol xinafoate (SX) in the treatment of COPD during 6-month‘s in conditions of Eastern Siberia (ES)
I. N. Trofimenko, B. A. Chernyak (Irkutsk, Russia)
| |
High dose inhaler corticosteroids in patients with COPD
H. Turker, Z. Karakurt, M. Durucu, E. Sulu, S. Boga, M. Yavsan (Istanbul, Turkey)
| |
Cardiovascular safety of long-term therapy with combination bronchodilator in patients with stable COPD
T. S. Onyshchenko (Dnipropetrovsk, Ukraine)
| |
The effect of dipyrone on respiratory function in chronic obstructive pulmonary disease (COPD)
E. Gulmez, C. Tulunay, S. Beder, O. Kayacan, D. Karnak (Ankara, Turkey)
| |
The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD
M. D. Spencer, N. Karia, J. Anderson (Greenford, United Kingdom)
| |
Modelling the beneficial impact of inhaled corticosteroids on health outcomes among COPD patients
Y. Punekar, A. Briggs, M. Spencer (Greenford, Oxford, United Kingdom)
| |
The effects of nebulised bronchodilators and corticosteroids treatment compared with inhaled drug therapy for moderate COPD patients
K. V. Doboch, T. A. Stepanenko, P. K. Yablonsky (St-Petersburg, Russia)
| |
Theophyllin and cerebral hemodynamic in COPD patients
G. K. Sharafutdinova, L. A. Nazyrova, E. M. Khodjaeva, N. U. Sharapov (Tashkent, Uzbekistan)
| |
Chest physiotherapy changed the ventilatory mechanics in patients with COPD
K. Matsumoto, H. Kurosawa, Y. Sano, N. Mori, Y. Goto, W. Hida, M. Kohzuki (Sendai, Japan)
| |
Dose delivery characteristics of two dry powder inhalers in COPD patients
C. J. Badiola, J. L. Izquierdo (Madrid, Guadalajara, Spain)
| |
Inspiratory profiles and resistance of two dry powder inhalers in COPD patients
C. J. Badiola, J. L. Izquierdo (Madrid, Guadalajara, Spain)
| |
Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol
M. K. Hunjan, D. T. Williams (Uxbridge, United Kingdom)
| |